VC-backed Zafgen nabs $20 mln from Oxford and MidCap Financial

Zafgen has secured a $20 million loan from Oxford and MidCap Financial. Based in Cambridge, Mass., Zafgen is a biopharmaceutical company focused on treating severely obese patients. Zafgen’s investors include RA Capital Management, Brookside Capital, Venrock and Alta Partners.

Lumena attracts $45 mln in Series B funds

Lumena Pharmaceuticals said Tuesday that it has closed $45 million in Series B financing. New Enterprise Associates led the round with participation from Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders.

Kite Pharma Completes $35m Financing

Kite Pharma, a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, has closed a $20 million private placement of shares of its Series A Preferred Stock. Joined by a new investor, Alta Partners, all existing major investors participated in the financing.

Kiadis Pharma Secures Financing

Kiadis Pharma, a clinical stage biopharmaceutical company developing treatments for blood cancers, has raised 10 million euros ($12.8 million) in an equity financing round. The round was led by Life Sciences Partners and supported by a large investment from DFJ-Esprit. Other investors included Alta Partners, Quest for Growth and NOM.

Sutro Biopharma Secures More Funds Led by Skyline Ventures

San Francisco-based Sutro Biopharma has closed a $16.5 million second tranche of its Series C financing. The financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. Sutro has raised almost $60 million since its founding in 2003. PRESS RELEASE Sutro Biopharma today announced the […]

aTyr Pharma Appoints Board Member

Protein therapeutics company aTyr Pharma has appointed R. Alan Ezekowitz to aTyr’s Therapeutic advisory board. Physician scientist Dr. Ezekowitz has led various research and development programs at Merck. The privately-held biotech company was founded by The Scripps Research Institute Professor Paul Schimmel and is backed by life sciences investors Alta Partners, Cardinal Partners, Domain Associates […]

Pfizer Buys Excaliard Pharmaceuticals

Pfizer Inc. is buying Excaliard Pharmaceuticals Inc. for an undisclosed amount. Excaliard develops drugs for the treatment of skin fibrosis. Excaliard Pharmaceuticals previously raised venture financing from Alta Partners, ProQuest Investments and RiverVest Venture Partners.

SARcode Bioscience Inks $44M Series B

Brisbane, Calif.-based SARcode Bioscience has closed on $44 million in Series B financing, led by Sofinnova Ventures. Rho Ventures also participated, as did existing investors Alta Partners and Clarus Venture Partners. The money will go toward clinical development of the company’s treatment for dry eye syndrome.

Aerie Pharmaceuticals Closes $30M Series B

Aerie Pharmaceuticals Inc., a biotechnology company focused on medical innovations in ophthalmology, has closed $30 million in Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners and existing investors Alta Partners and TPG Biotech. Aerie Pharmaceuticals has offices in Research Triangle Park, N.C. and in Bridgewater, N.J.

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget